After three years on the Committee for Research, Linda Hiraki, MD, ScD, has stepped into the role of chair. During her term, she aims to foster global connections to advance and expand the positive impact of rheumatology research.
Search results for: hospital
The Biosimilar Economic Conundrum: Where We Stand
Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.
The 2023 ARP Merit Awards
SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP Merit Awards and ARP Master class, recognizing outstanding contributions to the field of rheumatology. The…
Community Practice Rheumatology Is Challenging, But Rewarding, Too
Community practice rheumatology may be a less-followed path within the specialty, and it brings with it certain challenges. However, it also offers rewards, such as autonomy and deep relationships with patients. The Rheumatologist recently interviewed three community practice rheumatologists from around the U.S. to find out about their approaches to patient management, staffing and other…
Advice for Authors: Editors Provide Tips & Tricks for Getting Your Work Published
Researchers and physician-scientists often need practical advice for getting their work published. Here are insights into how to select an appropriate publication, manage co-author relationships and more from a panel of experts in both rheumatology and publishing.
Pregnancy Outcomes in Patients Treated with TNF Inhibitors
A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
Insight into the FDA Approval of Ustekinumab Biosimilar
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
Dr. Hasan Yazici in the Spotlight
In 1937, the Turkish physician Hulusi Behçet described a number of patients with relapsing aphthous ulcers in the mouth and over the genitalia, as well as hypopyon iritis. Since that time, the eponymous condition, known as Behçet’s disease, has been recognized as a multisystem vasculitis that can present with myriad other signs and symptoms. Although…
The Role of Empathy in Therapeutic Relationships
I couldn’t help but roll my eyes. I was at a mandatory “training session” on patient communication for all clinicians at my institution. There, I was being coached on how to properly talk to patients. In theory, this isn’t a bad thing—we all need more education on how to facilitate inclusive and equitable conversations with…
Get AMPed: Understanding RA Through the Accelerating Medicines Partnership
SAN DIEGO—The Accelerating Medicines Partnership (AMP) is a public-private collaboration involving the National Institutes of Health (NIH), the U.S. Food & Drug Administration (FDA), multiple biopharmaceutical and life science companies, and nonprofit organizations, all joined together with the goal of transforming diagnosis and treatments for a multitude of diseases. One such condition that has been…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 329
- Next Page »